Metrics to compare | CTXR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCTXRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.3x | −0.9x | −0.2x | |
PEG Ratio | −0.01 | −0.17 | 0.00 | |
Price/Book | 0.2x | 11.5x | 2.6x | |
Price / LTM Sales | 2.0x | 2.0x | 2.7x | |
Upside (Analyst Target) | - | 97.8% | 68.5% | |
Fair Value Upside | Unlock | 20.6% | 11.5% | Unlock |
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company’s late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.